Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glycopyrronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 15/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 8/20 | 1.00 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 1.00 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 1.00 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycopyrronium SCHEMBL41436 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL1900235 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL2012259 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL417981 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL417980 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL132614 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL131054 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Glycopyrronium SCHEMBL4106576 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Hexopyrronium SCHEMBL5391795 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2KCNH2CHRM4CHRM5 | |
| Hexopyrronium SCHEMBL915388 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2KCNH2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255794-A1 | TOPICAL FORMULATION OF AN ANTICHOLINERGIC COMPOUND FOR TREATING SEVERE HYPERHIDROSIS AND EXCESSIVE SWEATING | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2025-08-14 | — | — | US | claimed |
| EP-3603634-B1 | PHARMACEUTICAL COMPOSITION CONTAINING GLYCOPYRROLATE AND A BETA2 ADRENOCEPTOR AGONIST | NOVARTIS AG (CH) | 2025-02-12 | — | — | EP | claimed |
| EP-4333831-B1 | TOPICAL FORMULATION OF AN ANTICHOLINERGIC COMPOUND FOR TREATING SEVERE HYPERHIDROSIS AND EXCESSIVE SWEATING | DR AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL (DE) | 2024-08-14 | — | — | EP | claimed |
| EP-4260852-A1 | TOPICAL FORMULATION OF AN ANTICHOLINERGIC COMPOUND FOR TREATING SEVERE HYPERHIDROSIS AND EXCESSIVE SWEATING | Dr. August Wolff GmbH & Co. KG Arzneimittel (DE) | 2023-10-18 | — | — | EP | claimed |
| US-11191713-B2 | Oil in water emulsion | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2021-12-07 | — | — | US | claimed |
| US-20210290536-A1 | TOPICAL EMULSION OF AN ANTICHOLINERGIC COMPOUND | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2021-09-23 | — | — | US | claimed |
| US-20200101005-A1 | Oil in Water Emulsion | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2020-04-02 | — | — | US | claimed |
| EP-3603634-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLYCOPYRROLATE AND A BETA2 ADRENOCEPTOR AGONIST | Novartis AG (CH) | 2020-02-05 | — | — | EP | claimed |
| EP-3431072-B1 | OIL IN WATER EMULSION | DR AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL (DE) | 2019-11-06 | — | — | EP | claimed |
| US-20190282561-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2019-09-19 | — | — | US | claimed |
| US-20080317862-A1 | Organic Compounds Comprising a Glycopyrrolium Salt | COLLINGWOOD STEPHEN PAUL | 2008-12-25 | — | — | US | claimed |
| US-20080286363-A1 | (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one maleate; 3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide (glycopyrrolate), and a glucocorticosteroids | COLLINGWOOD STEPHEN PAUL | 2008-11-20 | — | — | US | claimed |
| US-20080279948-A1 | Treatment of Asthma and Copd Using Triple-Combination Therapy | NXP B.V. (NL) | 2008-11-13 | — | — | US | claimed |
| US-20080274189-A1 | Organic Compounds Comprising a Glycopyrr Onium Salt | COLLINGWOOD STEPHEN PAUL | 2008-11-06 | — | — | US | claimed |
| US-20080267886-A1 | Such as 8-hydroxy-5-[1-hydroxy-2-(indan-2-ylamino)-ethyl]-1H-quinolin-2-one; for treatment of inflammatory or obstructive airways diseases | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | claimed |
| EP-1894568-A1 | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases | Novartis AG (CH) | 2008-03-05 | — | — | EP | claimed |
| US-20070185067-A1 | Ciclesonide and glycopyrronium combination | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| US-20070167496-A1 | Roflumilast and glycopyrronium combination | ATTANA PHARMA AG (DE) | 2007-07-19 | — | — | US | claimed |
| EP-1720577-A2 | CICLESONIDE AND GLYCOPYRRONIUM COMBINATION | Altana Pharma AG (DE) | 2006-11-15 | — | — | EP | claimed |
| WO-2005082413-A2 | CICLESONIDE AND GLYCOPYRRONIUM COMBINATION | ALTANA PHARMA AG (DE) | 2005-09-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274189-A1 | Organic Compounds Comprising a Glycopyrr Onium Salt | CHRM3, NR3C1, NR3C2 | CHRM3 1/4885CHRM2 15/4885CHRM4 7/4885 |
| US-20080279948-A1 | Treatment of Asthma and Copd Using Triple-Combination Therapy | MC2R, GALR3, CHRM3 | CHRM3 3/4885CHRM2 9/4885CHRM4 28/4885 |
| US-20070185067-A1 | Ciclesonide and glycopyrronium combination | NR3C2, NR3C1, NR5A1 | CHRM3 74/4885CHRM2 412/4885CHRM4 302/4885 |
| US-20070167496-A1 | Roflumilast and glycopyrronium combination | ADAMTS5, TPO, ADAMTS4 | CHRM3 18/4885CHRM2 85/4885CHRM4 151/4885 |
| US-20080286363-A1 | (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one maleate; 3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide (glycopyrrolate), and a glucocorticosteroids | NR3C1, NR3C2, MGAT3 | CHRM3 9/4885CHRM2 61/4885CHRM4 63/4885 |
| US-20190282561-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | CHRM3 14/4885CHRM2 8/4885CHRM4 33/4885 |
| US-20080317862-A1 | Organic Compounds Comprising a Glycopyrrolium Salt | CHRM3, NR3C1, MUC1 | CHRM3 1/4885CHRM2 15/4885CHRM4 5/4885 |
| US-20080267886-A1 | Such as 8-hydroxy-5-[1-hydroxy-2-(indan-2-ylamino)-ethyl]-1H-quinolin-2-one; for treatment of inflammatory or obstructive airways diseases | GALR1, GALR3, GALR2 | CHRM3 6/4885CHRM2 11/4885CHRM4 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.